MENU
CAPR
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Capricor Therapeutics (CAPR) Earnings Date & Reports

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs... Show more

Industry: #Biotechnology
A.I. Advisor
published Earnings

CAPR is expected to report earnings to fall 29.84% to -51 cents per share on March 11

Capricor Therapeutics CAPR Stock Earnings Reports
Q4'26
Est.
$-0.51
Q3'26
Missed
by $0.12
Q2'26
Missed
by $0.10
Q1'26
Missed
by $0.07
Q4'25
Missed
by $0.11
The last earnings report on November 10 showed earnings per share of -73 cents, missing the estimate of -61 cents. With 2.38M shares outstanding, the current market capitalization sits at 523.25M.
A.I.Advisor
Nov 10, 2026

Capricor Therapeutics (CAPR) Earnings Preview: Regulatory Momentum Meets a Key Quarterly Update

Key Takeaways

  • Capricor Therapeutics (NASDAQ: CAPR) is expected to report results for its third quarter ended September 30, 2026, with the exact date still to be confirmed by the company.
  • The company remains pre-revenue, with analyst forecasts showing a wide range that reflects uncertainty around the timing of a potential commercial launch of its lead therapy, deramiocel.
  • Investors will be watching closely for updates on the amended Biologics License Application (BLA) — the formal request for U.S. marketing approval — for deramiocel in Duchenne muscular dystrophy (DMD).
  • Capricor's most recent quarter (Q2 2026) showed a wider-than-expected net loss of roughly $40.7 million, driven by higher research and development (R&D) and general and administrative (G&A) spending.
  • Regulatory progress, cash runway, and pre-commercialization spending are expected to matter more to the stock than the headline loss figure.
  • You can find more details about this ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
  • Explore Trending AI Robots to discover automated trading strategies currently drawing attention in the market.

Earnings Context and Why It Matters

Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapies, with its lead candidate deramiocel aimed at treating the cardiac complications of Duchenne muscular dystrophy. Because the company has not yet begun generating product revenue, its quarterly results are less about the bottom line and more about regulatory progress, spending discipline, and the strength of its balance sheet. This report arrives at a pivotal moment: the U.S. Food and Drug Administration (FDA) has agreed to review an amended application focused on an upper-limb indication, and investors are eager for clarity on the approval timeline. For shareholders, the earnings event doubles as a progress check on a potentially transformative commercial launch.

Earnings Expectations

Because Capricor is pre-commercial and has reported zero product revenue in recent quarters, consensus estimates for the third quarter remain highly uncertain and vary considerably across sources. Widely cited forecasts put the quarterly loss per share at roughly $0.13, though individual estimates range from about $0.13 to $0.44 per share, reflecting limited visibility into spending and launch timing. Revenue expectations are similarly spread, spanning from approximately $10 million to more than $41 million depending on whether analysts model any early milestone or collaboration-related income.

For context, Capricor posted a net loss of $0.54 per share in the third quarter of 2025. In the most recent quarter (Q2 2026), the company reported a loss of $0.70 per share, wider than consensus, alongside roughly $237.9 million in cash and cash equivalents. Historically, the stock has reacted more sharply to regulatory and clinical news than to the headline earnings figure, and this quarter is likely to follow that pattern.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and broader market opportunities more efficiently than manual screening. For investors tracking names like Capricor Therapeutics, it offers a structured way to monitor shifting momentum and identify comparable opportunities across the biotechnology sector.

Market Reaction and Investor Sentiment

Sentiment heading into this report is heavily influenced by regulatory developments rather than quarterly financials. In August 2026, Capricor shares surged sharply in after-hours trading after the company disclosed that the FDA had agreed to review its amended BLA for deramiocel focused on an upper-limb indication, with an extension of the PDUFA (Prescription Drug User Fee Act) goal date expected. That news reset investor expectations around the approval pathway, even as the stock has since experienced meaningful volatility.

Key risk factors to watch include the timing and outcome of the FDA review, the pace of pre-commercialization spending, and any updates on the company's manufacturing readiness. A wider-than-expected loss could weigh on shares, but regulatory commentary on the call is likely to be the dominant driver of the market's reaction.

Forward Outlook and Key Factors to Monitor

Looking beyond the quarterly numbers, investors should focus on the regulatory pathway for deramiocel. The most important catalyst is the amended BLA review and the expected PDUFA goal-date extension, which will shape the timeline for a potential U.S. launch. Any additional clarity from the FDA — including requests for further data or the scheduling of an advisory committee meeting — could move the stock in either direction.

Manufacturing and commercial readiness are also central. Capricor has said its San Diego facility is operational for a potential launch, with full expansion validation expected in 2027. Watch for updates on capacity, supply agreements, and progress with its commercial partner as the company transitions toward potential commercialization.

Finally, monitor spending and the balance sheet. The company ended its last quarter with roughly $237.9 million in cash, but rising R&D and G&A costs, including legal expenses tied to its partnership dispute and pre-launch initiatives, will determine how far that runway stretches. Cost discipline and any revenue or collaboration milestone recognition will be important signals in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Develops innovative products for the treatment of cardiovascular diseases

Industry Biotechnology

Industry
Biotechnology
Address
10865 Road to the Cure
Phone
+1 858 727-1755
Employees
160
Web
https://www.capricor.com